34: Baseline cytokine levels according to IMDC score in patients with metastatic clear cell renal cell carcinoma treated with nivolumab in the NIVOREN GETUG-AFU 26 Translational study
Research fellow Institut Gustave Roussy Paris, Ile-de-France, France
Background: The NIVOREN GETUG-AFU 26 translational study explored baseline cytokine correlation with outcomes under nivolumab. We previously reported 5 candidate biomarkers (IL-6/IL-8/IL-7/VEGF/4-1BB). Here, we report the cytokines baseline concentration according to IMDC risk group.
Methods: A panel of 8 cytokines (VEGF,VCAM-1,IL-6,IL-7,IL-8,BAFF,4-1BB and CXCL13) was quantified before treatment using the MSD-assay. Patients were classified into IMDC groups good (GR), intermediate (IR) or poor (PR). Data were interpreted using the Kruskal-Wallis test.
Results: Overall, 353 patients were included. The IMDC risk score breakdown was 19% good, 55.4% intermediate and 25.6% poor. Patients with worse IMDC score were significantly enriched in several cytokines (Table 1).
Conclusions: Baseline cytokine levels are strongly related to IMDC risk group: patients with worse IMDC were gradually enriched in cytokines. Baseline cytokines should be investigated in addition to currently used prognostic tools.